
    
      The study is designed as a prospective, open-label, nonrandomized trial involving
      participants of both genders aged 18-35 years with Keratoconus planned for routine corneal
      crosslinking at the Department of Ophthalmology, Umeå University Hospital, Umeå, Sweden.

      The study includes 30 participants with unilateral Keratoconus, receiving Epi-on PiXL in high
      oxygen environment (n=30). All patients are informed about the procedures before consenting
      to participate in the study.

      At baseline, before treatment, each eye is examined with slit-lamp microscopy, subjective
      refraction, determination of uncorrected (UCVA), low contrast visual acuity at 2.5 percentage
      contrast and 10 percentage contrast and best corrected (BSCVA) visual acuities using the
      LogMAR fast protocol and intraocular pressure (IOP) using Goldmann applanation tonometry.
      Under standardized, mesopic light conditions each eye is evaluated by keratometry readings
      and central corneal thickness, extracted from Schemipflug camera measurements, Pentacam HR®
      (Oculus, Inc. Lynnwood, WA) and AS-OCT (Fourier domain OCT CASIA2, Tomey Technology and
      vision, Germany).

      Central corneal endothelial photographs are taken with the Topcon SP-IP specular microscope
      (Topcon Europe B.V., Capelle a/d Ijssel, the Netherlands) and total ocular wavefront is
      measured with iTrace (Tracey Technologies, Inc.).

      Ocular discomfort is subjectively evaluated in each eye by a specific visual analogous rating
      scale at 4h, 8h, 12h, 24h and thereafter daily up to 1 week postoperatively.

      All the above mentioned examinations are repeated at 1, 3, 6, 12 and 24 months after
      treatment. At 1 day and 1 week after treatment, solely UCVA, Auto refractor measurements,
      slit-lamp examination are evaluated.
    
  